An interventional study of AP029 mix and Placebo in Diabetes in Adolescence and PreDiabetes, sponsored by AronPharma Sp. z o. o.. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-16.
Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Prediabetic State with a site in Poland — 6 open to participants now, 6 under way, none of them phase 3. Prediabetic State · Poland.
Among the 11 studies in Prediabetic State with a site in Poland, this one is the only one that started in 2023, is one of 6 with no phase, and was the 9th registered.
919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.
Browse Prediabetic State studies →6 of the 11 studies in Prediabetic State with a site in Poland are open now. Recruiting first, the newest first:
National Institute of Cardiology, Warsaw, Poland · Sites in Poland
Ages 18–80
PolTREG S.A. · Sites in Poland
Ages 3–18
Medical University of Bialystok · Sites in Poland
Ages 18–65 · Healthy volunteers
Medical University of Bialystok · Sites in Poland
Healthy volunteers
Medical University of Bialystok · Sites in Poland
Ages 18+ · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 62 across 763 interventional studies indexed under Prediabetic State.
Median enrollment 300 across the 9 interventional studies, 5,500 across the 2 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 8 most frequent:
AronPharma Sp. z o. o. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
AronPharma Sp. z o. o. has 1 study filed under Prediabetic State — fewer than ten, so there is no comparison to draw.
1 of the studies in Prediabetic State with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634591Medical University of BialystokThe Bialystok Bariatric Surgery Study | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Prediabetic State with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to demonstrate that a daily supplementation of AP029 Mix: I) has a positive effect on reducing side effects of metformin, while enhancing the therapeutic effect of metformin; II) normalizes prediabetes biomarkers in order to prevent further progression into diabetes.
Randomized, double-blind, cross over study conducted under medical supervision on 1) group of 20 patients with type II diabetes and 2) group of 10 patients with prediabetes.
Study design: 2 months of AP029 supplementation, 1 month wash-out, 2 months of placebo intake. Patients will attend 4 visits. On each visit, the following parameters are analyzed: level of glucose, insulin, HbA1c, hsCRP lipid panel (total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), HDL) and inflammatory and oxidative stress markers. In addition, a questionnaire of symptoms associated with metformin intake will be conducted
Inclusion Criteria for type II diabetes:
Inclusion Criteria for prediabetes:
Exclusion Criteria for type II diabetes:
Exclusion Criteria for prediabetes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with type II diabetes receiving metformin for up to 5 months
Dietary Supplement: AP029 mix
Patients with pre-diabetic
Dietary Supplement: AP029 mix
Patients with type II diabetes receiving metformin for up to 5 months
Other: Placebo
Patients with pre-diabetic
Other: Placebo
Polyphenol-rich plant extracts Twice a day
Twice a day
Glucose level
Comparison of glucose level
Time frame: Baseline, 2 months, 3 months, 5 months
Insulin level
Comparison of insulin level
Time frame: Baseline, 2 months, 3 months, 5 months
Discomfort related to metformin side effects
Based on questionnaire
Time frame: Baseline, 2 months, 3 months, 5 months
Lipid panel (total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), HDL)
Comparison of lipid panel markers
Time frame: Baseline, 2 months, 3 months, 5 months
hsCRP level
Comparison of hsCRP level
Time frame: Baseline, 2 months, 3 months, 5 months
HbA1c level
Comparison of hbA1c level
Time frame: Baseline, 2 months, 3 months, 5 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Nov 2023, 6 months after the start.
Of 46 industry-sponsored interventional studies with no phase under Prediabetic State, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 6 months is below that.
Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AronPharma Sp. z o. o.